New drug doubles 1-year survival in pancreatic cancer trial
medicalxpress - Pancreatic cancer is one of the deadliest cancers and among the hardest to treat, with most patients surviving less than a year after diagnosis. But a new drug developed at Northwestern University may soon help patients live longer.
AI Summary: A Phase 3 study showed a novel agent markedly lengthened survival for people with metastatic pancreatic cancer, roughly doubling one-year survival versus standard care. The results, from the RASolute 302 program evaluating daraxonrasib/Revolution Medicines’ approach, represent an uncommon advance in a stubbornly lethal disease and could change treatment standards pending regulatory review.
- Clinicians celebrate landmark KRAS win; cautious optimism prevails (7)
- Daraxonrasib Phase 3: drug doubles one-year survival (5)
- Market scramble: Revolution Medicines' fundraising and buyout buzz (3)
- Other pancreatic research, methods and early-stage KRAS studies (5)
- All Other Stories
Clinicians celebrate landmark KRAS win; cautious optimism prevails
Daraxonrasib Phase 3: drug doubles one-year survival
Market scramble: Revolution Medicines' fundraising and buyout buzz
Other pancreatic research, methods and early-stage KRAS studies
All Other Stories
Related Stories
FDA grants early access to experimental pancreatic cancer drug / 2 months
FDA clears pivekimab sunirine (Decnupaz) as first BPDCN ADC / 6 wks
FDA to revisit Atara/Pierre Fabre cell therapy approval for rare lymphoma / 2 months
FDA advisory panel rejects camizestrant after SERENA‑6 results / 2 months
Phase 2 POLAR reports pembrolizumab plus olaparib outcomes in HRD pancreatic cancer / 3 months
Daraxonrasib’s ASCO moment sparks rapid clinical uptake for pancreatic cancer / 13 days
FDA greenlights datopotamab deruxtecan for metastatic TNBC / 14 days
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Infant Health, Oncology, Supply Chain, Olfaction and look for the RSS link.
StackHealth Time Machine